Showing 7421-7430 of 8796 results for "".
- Consumer Reports IDs Teaching Hospitals That Expose Patients to Central Line Infectionshttps://practicaldermatology.com/news/consumer-reports-ids-teaching-hospitals-that-expose-patients-to-central-line-infections/2458366/Too many teaching hospitals are still exposing patients to dangerous bacteria via central line infections, according to Consumer Reports. The new report identifies
- Food Allergy Linked to Early Exposure Through Broken Skinhttps://practicaldermatology.com/news/food-allergy-linked-to-early-exposure-through-broken-skin/2458369/Early exposure to a food allergen through broken skin might prompt the development of food allergy, according to new research in Allergy and Asthma Proceedings. This theory gained further support from a recent study that fo
- FDA Clears Syneron Candela's Profound SubQ to Improve Cellulitehttps://practicaldermatology.com/news/fda-clears-syneron-candelas-profound-subq-to-improve-cellulite/2458381/Syneron Candela received FDA 510(k) clearance for Profound when using the SubQ handpiece and cartridge to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III, as supported by long term data (6 months). A recent multi-center clinical study of Profound sh
- Bob Rhatigan Joins ALASTIN Skincare's Board of Directorshttps://practicaldermatology.com/news/bob-rhatigan-joins-alastin-skincares-board-of-directors/2458384/Bob Rhatigan is joining ALASTIN Skincare™, Inc’s Board of Directors effective December 2016. Mr. Rhatigan most recently served as President and Chief Operating Officer at Alphaeon Corporation. Prior to this, he spent 17 years at Allergan In
- New Interim CEO Named For Canada's Crescitahttps://practicaldermatology.com/news/new-interim-ceo-for-canadas-crescita/2458386/Dan Chicoine is now the interim Chief Executive Officer of Crescita Therapeutics Inc., a commercial dermatology company in Canada. He is replacing Greg Orleski. Mr. Chicoine will also continue to serve as the Company's Executive
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu
- Scleroderma Treatment Breakthrough? New Study Hints At Way To Slow Skin Fibrosishttps://practicaldermatology.com/news/scleroderma-treatment-breakthrough-new-study-suggests-way-to-slow-skin-fibrosis/2458387/New and ongoing research at Hospital for Special Surgery (HSS) in New York City has identified a possible mechanism behind the fibrosis that occurs in scleroderma – a mechanism that may one day lead to a treatment for the disease. The findings appear in the
- Avon Chooses Greenwich, CT Dermatologist to Champion ANEW Brandhttps://practicaldermatology.com/news/avon-chooses-greenwich-conn-dermatologist-to-champion-anew-brand/2458390/Kim Nichols, MD, is now Avon’s new consulting dermatologist. In her role, the Greenwich, Conn.-based dermatologist will help to educate Avon Representatives on the technology behind the
- Brenton L. Saunders is Allergan's New Chairman of the Boardhttps://practicaldermatology.com/news/brenton-l-saunders-is-allergans-new-chairman-of-the-board/2458389/Brenton L. Saunders is Allergan’s new Chairman of the Board, the company reports. Effective today, Saunders will replace Paul Bisaro, who served as Executive Chairman since July 1, 2014. Bisaro will remain a member of the Allergan Board of
- Biofrontera Launches Ameluz for Actinic Keratosishttps://practicaldermatology.com/news/biofrontera-launches-ameluz-for-actinic-keratosis/2458397/Biofrontera AG initiated the US commercial launch of its combination topical prescription drug Ameluz and medical device BF-RhodoLED, which has been FDA approved to treat mild to moderate actinic keratosis (AK) on the face and scalp. Ameluz is used in combination with the medical device B